Invizyne, the first startup to join our MOST-IP incubator in fall of 2019, has been fantastically successful. In just a little more than a year, the company has been awarded several phase 1 and phase 2 SBIR grants since then and the team has grown accordingly. A great company run by great people attracting great talent. Congratulations!
Invizyne is a synthetic biology company specialized in cell-free synthesis of specialty chemicals. It’s a very hot field and a platform technology at the interface of pharmaceuticals, biofuels and renewables.
Curious to hear how they did it? Join this month’s MADIA Tech Launch virtual meetup
Wednesday Feb. 10 at 6:30pm
The Future of Biomanufacturing
Streamlining Synthetic Biology and Simplifying Production
Dr. Tyler Korman
Cofounder and Director of R&D at Invizyne